Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives Average Recommendation of Moderate Buy from Analysts

Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the seven analysts that are presently covering the company, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 […]

Related Keywords

Blackrock ,Nova Scotia ,Canada ,Montreal ,Quebec ,Switzerland ,Swiss ,Anna Protopapas ,Robertw Baird ,Brian Deschuytner ,Jpmorgan Chase Co ,Securities Exchange Commission ,Blackrock Inc ,Citigroup ,Janssen Biotech Inc ,Mersana Therapeutics Inc ,Asana Biosciences ,Swiss National Bank ,Merck Kgaa ,Hermes Inc ,Nasdaq ,Merck Kga ,Mersana Therapeutics ,Get Free Report ,Exchange Commission ,Director Anna Protopapas ,National Bank ,Montreal Can ,Federated Hermes ,Get Free ,Janssen Biotech ,Ares Trading ,Mersana Therapeutics Daily ,Nasdaq Mrsn ,Mrsn ,Medical ,Ratings ,Consensus ,